Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors

NCT06874335 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT06874335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06874335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 20, 2025
Completion date
March 31, 2029
Enrollment
140 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor